Amarin’s Vazkepa (icosapent ethyl) Receives NICE Recommendation for the Treatment of Cardiovascular Disease
- The NICE has issued FAD recommending the use of Vazkepa as a treatment option for adult statin-treated patients & for reimbursement and routine use in the NHS in England & Wales to reduce the high risk who have elevated triglycerides & eCVD. The final guidance is expected to be published in July 2022 & the product should be available on all local NHS formularies within 3mos.
- The P-III (REDUCE-IT) trial showed a 25% relative reduction & 4.8% absolute risk reduction in 1st occurrence of MACE, well-managed LDL-C levels are still at risk of a CV event & other factors
- Vazkepa is expected to be available in ~6 EU countries in 2022. The product has also won reimbursement approval in Sweden & is under review in other EU markets
Ref: Globenewswirw Image: Amarin
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].